Statement from Human Longevity Inc. on PNAS Paper on Face and other Trait Predictions from Whole Genome Sequencing and Machine Learning for Identification of Individuals

September 5, 2017 As outlined in a peer reviewed study recently published in the journal, Proceedings of the National Academy of Sciences (PNAS), Human Longevity researchers set out to see what traits could be predicted and thus used to identify individuals applying machine learning algorithms to whole genome data, without assuming any additional information such Continue Reading

Continue Reading

Researchers from Human Longevity, Inc. Use Whole Genome Sequence Data and Machine Learning to Identify Individuals Through Face and Other Physical Trait Prediction

(SAN DIEGO, CA)—September 5, 2017—Researchers from Human Longevity, Inc. (HLI) have published a study in which individual faces and other physical traits were predicted using whole genome sequencing data and machine learning. This work, from lead author Christoph Lippert, Ph.D. and senior author J. Craig Venter, Ph.D., was published in the journal Proceedings from the Continue Reading


Human Longevity, Inc. Researchers Develop New Algorithm to Rapidly and Accurately Predict HLA Types Using Illumina Next Generation Sequencing Technology

(SAN DIEGO, CA)—July 3, 2017—Researchers from Human Longevity, Inc. (HLI) have developed a new algorithm called xHLA to rapidly and accurately determine the sequence of the human leukocyte antigen (HLA) gene region from 30x whole genome sequencing using Illumina HiSeq X10 and NovaSeq sequencing technology. This work was published by lead author Chao Xie, Ph.D. Continue Reading


Human Longevity, Inc. Announces Agreement with Merck KGaA, Darmstadt, Germany to Engage in Cancer Biomarker Discovery in Advanced Melanoma

(SAN DIEGO, CA)—June 15, 2017—Human Longevity, Inc. (HLI), the genomics-powered, health intelligence company, announced today that the company has signed an agreement with Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the U.S. and Canada, with the goal of pioneering the application of advanced genomics and expert analysis with machine Continue Reading


Saturnino (Nino) Fanlo Joins Human Longevity, Inc. as Chief Financial Officer

Financial Industry Leader Brings 30 Years of Experience Leading Public, Private Companies; Raising Billions in Financing Rounds (SAN DIEGO, CA)—May 25, 2017—Human Longevity, Inc. (HLI), the genomics-based, health intelligence company, announced today that Saturnino (Nino) Fanlo will be joining the company as Chief Financial Officer, reporting to CEO Cynthia Collins. Fanlo brings decades of financial Continue Reading

Media Resources

HLI Fact Sheet